MYBANK
30.4.2024 15:42:35 CEST | Business Wire | Press release
MYbank, a leading digital bank in China and an associate of Ant Group, today released its 2023 Annual Report, which announces that the bank has cumulatively served over 53 million small and micro-sized enterprises (SMEs) as of the end of 2023. The report also highlights MYbank’s continued investment in technology, with 36% of its operating expenses allocated to tech and over 64% of its workforce comprising of tech talents.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430942970/en/
MYbank makes financing more accessible for 53 million SMEs (Graphic: Business Wire)
“MYbank remains committed to supporting SMEs’ funding needs amidst ongoing economic and technological transformations. As a technology-driven bank, MYbank will enhance its capabilities through continuous exploration of AI and other emerging technologies, aiming to make finance more inclusive for all,” said MYbank President Feng Liang.
Leveraging Ant Group’s self-developed Bailing foundational model and other new technologies, MYbank enables better-informed lending decisions, making financing more accessible to its extensive base of SME clients, all without the need for physical branches.
In the field of supply chain finance across industries, MYbank's Goose System employs AI-powered knowledge graph capabilities to map out SMEs across entire industry supply chains. Furthermore, the system enhances the bank's ability to assess SMEs' business status and creditworthiness through automated analysis of industry research reports.
In the automobile sector alone, the Goose System has served over 1 million SMEs, 64% of which obtained collateral-free loans for the first time. These loans enabled SMEs to undertake more orders, leading to an average monthly delivery volume increase of 17%.
MYbank has continuously enhanced its AI-powered conversational risk control solution, Lark System, to optimize credit line management for SMEs. Lark operates as a 24/7 digital customer service manager, automating customer interactions and processing various types of customer-uploaded information. Leveraging multimodal analysis, Lark accurately assesses customer needs and delivers tailored credit lines. As of the end of 2023, Lark had served over 8 million SME clients with an average credit limit increase of RMB 45,000 per customer.
In agricultural finance, MYbank has been expanding the coverage of its Tomtit System, which utilizes satellite remote sensing technology to identify crop types and estimate the agricultural output of specific farmlands that growers marked on a digital map. This system enhances the bank's ability to assess potential credit risks more accurately, empowering it to make informed credit decisions when farmers apply for collateral-free loans. By the end of 2023, the Tomtit System can recognize 15 types of crops, and 1.69 million growers across China’s 31 provinces have received online loans through the system.
Through continuous investment in technology, MYbank successfully meets the typically frequent, urgent, and short-term funding requirements of SMEs. In 2023, over 72% of MYbank’s 3 million newly added loan recipients obtained businesses loans from a bank for the first time. Additionally, more than 60% of MYbank’s SME clients received loans with interest below 100 RMB, with the average loan size being 72,000 RMB.
About MYbank
Founded in 2015 with a focus on serving SMEs and farmers, MYbank was among the first group of pilot private commercial banks in China. It was also the first bank in China to deploy its core banking system entirely on the cloud without any physical branches.
MYbank pioneered the “310 model” for SME financing, which offers a collateral-free business loan that takes less than three minutes to apply on a mobile phone, less than one second to approve and requires zero human interaction.
In addition to advanced risk-management solutions, MYbank has harnessed technologies such as AI and remote sensing to streamline credit services for farmers. This approach eliminates the need for lengthy processes or paper documentation, making digital loans more accessible to them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430942970/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
